Beam Therapeutics, Inc. (BEAM)
27.59
-0.29
(-1.04%)
USD |
NASDAQ |
Feb 20, 16:00
27.73
+0.14
(+0.51%)
After-Hours: 20:00
Beam Therapeutics Cash from Financing (TTM) : 479.61M for Sept. 30, 2025
Cash from Financing (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Financing (TTM) Benchmarks
| Intellia Therapeutics, Inc. | 131.83M |
| Twist Bioscience Corp. | 10.89M |
| Pacific Biosciences of California, Inc. | -- |
| Stryker Corp. | 113.00M |
| Zimmer Biomet Holdings, Inc. | 326.00M |